Replicate Bioscience
Replicate Bioscience is developing RNA-based treatments for cancer using proprietary Synthetic Replicon for gene delivery (SynRGY) technology to deliver the genetic code of a virally derived RNA molecule.
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
Success Story
ATP Announces $40 Million in Series A Funding for srRNA Therapeutics Trailblazer Replicate Bioscience
NEW YORK and SAN DIEGO, Sept. 8, 2021 /PRNewswire/ — ATP, a leader in life sciences venture capital, today announced the launch of Replicate Bioscience, a company pioneering ways to prevent drug resistance in cancer, and treat autoimmune and inflammatory disorders and other diseases, using self-replicating RNA (srRNA). Replicate will use $40 million in committed Series A funding from ATP to advance multiple novel srRNA programs into clinical development.
Read the full story